New RA drug enters first human safety trial
Disease control
Recruiting now
This early-stage study tests a new drug, KT501, in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body handles the drug after a single injection. Participants must have had RA for at least 6 months and not responded well …
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC